Inovio Pharmaceuticals INO Insider Ownership

NASDAQ INO

$0.84 +0.04 (+5.48%)

At close: Oct 22, 2026 · 4:00 PM EDT

Insider Holdings by Owner

508.31K Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

0.377%

■0% pp QoQ

Shares Held by Insiders

390.13K

filed for Sep 2026

■0.00% QoQ

Shares Outstanding

103.40Mn

103,397,518 shares

Direct Holdings

389.76K

Indirect: 375

Net Shares Traded (QoQ)

no net change in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Across the past 12 months, Inovio Pharmaceuticals insiders reported no open-market purchases or sales.

Apart from open-market trades, INO insiders acquired 164.23K shares through option exercises and conversions and gave up 75.73K shares to cover taxes or exercise prices in the past 12 months.
Per Business Quant data, Inovio Pharmaceuticals insiders hold 390.13K shares in total based on their latest Form 4 filings, unchanged from 390.13K shares at the end of Q2 2026 and up 36.01% from 286.84K shares at the end of Q3 2025.
Direct holdings account for 389.76K shares (99.90%) of INO's insider total, and indirect holdings through trusts, partnerships and family members for 375 shares (0.10%).
The insider holdings in Inovio Pharmaceuticals belong to 11 insiders who have reported on Form 4 within the past two years.
Inovio Pharmaceuticals' three largest insider shareholders, based on their latest Form 4 filings, are Jacqueline Elizabeth Shea (Chief Executive Officer, 111.02K shares), David B. Weiner (Director, 87.59K shares) and Laurent Humeau (Chief Scientific Officer, 46.82K shares).
Of the shares held by INO insiders, 28.46% belong to Jacqueline Elizabeth Shea.
Institutions owned 33.03% of INO shares as of Q2 2026; insiders' latest Form 4 filings account for about 0.38%, leaving roughly 66.59% with other investors, including the public.
In the last 12 months, 25 Form 4 filings with transactions in INO stock came from 11 insiders.
This summary of Inovio Pharmaceuticals insider activity covers Form 4 filings through May 21, 2026.

Form 4 Holdings

Insiders Holding INO

Insiders 12

Shares held 508.31K

Of outstanding 0.492%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Jong Joseph Kim	Chief Executive Officer	118,548	118,548	23.3%	14 Mar, 2022
2	Jacqueline Elizabeth Shea	Chief Executive Officer	111,021	111,021	21.8%	21 May, 2026
3	David B. Weiner	Director	87,592	87,592	17.2%	27 Feb, 2026
4	Laurent Humeau	Chief Scientific Officer	46,823	46,823	9.2%	21 May, 2026
5	Peter Kies	Cfo	42,854	42,854	8.4%	21 May, 2026
6	Michael John Sumner	Chief Medical Officer	42,038	42,038	8.3%	21 May, 2026
7	Simon X Benito	Director	12,191	12,191	2.4%	21 May, 2025
8	Wendy L Yarno	Director	10,512	10,512	2.1%	21 May, 2025
9	Ann Calby Miller	Director	9,877	9,877	1.9%	21 May, 2025
10	Jay Shepard	Director	9,209	9,209	1.8%	21 May, 2025
11	Roger D Dansey	Director	8,916	8,916	1.8%	21 May, 2025
12	Lota S. Zoth	Director	8,726	8,726	1.7%	21 May, 2025

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

1,268 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
20 May, 2026	Wendy L Yarno	Director	Acquired A	41,800	$0.00	$0	41,800	Direct
20 May, 2026	Ann Calby Miller	Director	Acquired A	41,800	$0.00	$0	41,800	Direct
20 May, 2026	Lota S. Zoth	Director	Acquired A	41,800	$0.00	$0	41,800	Direct
20 May, 2026	Jay Shepard	Director	Acquired A	41,800	$0.00	$0	41,800	Direct
20 May, 2026	Peter Kies	Cfo	Acquired M	8,700	—	—	47,542	Direct
20 May, 2026	Roger D Dansey	Director	Acquired A	41,800	$0.00	$0	41,800	Direct
20 May, 2026	David B. Weiner	Director	Acquired A	41,800	$0.00	$0	41,800	Direct
20 May, 2026	Michael John Sumner	Chief Medical Officer	Acquired M	9,450	—	—	44,731	Direct
20 May, 2026	Laurent Humeau	Chief Scientific Officer	Acquired M	6,027	—	—	48,986	Direct
20 May, 2026	Simon X Benito	Director	Acquired A	41,800	$0.00	$0	41,800	Direct
20 May, 2026	Jacqueline Elizabeth Shea	Chief Executive Officer	Acquired M	28,296	—	—	123,327	Direct
20 May, 2026	Roger D Dansey	Director	Acquired A	34,200	$0.00	$0	34,200	Direct
20 May, 2026	David B. Weiner	Director	Acquired A	34,200	$0.00	$0	34,200	Direct
20 May, 2026	Peter Kies	Cfo	Disposed F	4,688	$1.23	$5.77K	42,854	Direct
20 May, 2026	Simon X Benito	Director	Acquired A	34,200	$0.00	$0	34,200	Direct
20 May, 2026	Ann Calby Miller	Director	Acquired A	34,200	$0.00	$0	34,200	Direct
20 May, 2026	Wendy L Yarno	Director	Acquired A	34,200	$0.00	$0	34,200	Direct
20 May, 2026	Jay Shepard	Director	Acquired A	34,200	$0.00	$0	34,200	Direct
20 May, 2026	Lota S. Zoth	Director	Acquired A	34,200	$0.00	$0	34,200	Direct
20 May, 2026	Laurent Humeau	Chief Scientific Officer	Disposed F	2,163	$1.23	$2.66K	46,823	Direct

Showing 1 to 20 of 1,268 transactions